Navigation Links
Endologix Reports 42% Second Quarter 2009 Revenue Growth
Date:7/22/2009

IRVINE, Calif., July 22 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, today announced financial results for the three months ended June 30, 2009.

"During the second quarter we continued to benefit from our recent new product launches and investments in our sales organization, leading to 42% year-over-year revenue growth and our first full quarter of positive cash flow from operations," said John McDermott, Endologix President and Chief Executive Officer. "We believe these results are indicative of the strength of our product differentiation and our ability to gain market share. As such, we have increased our full year 2009 revenue guidance to a range of $51 to $53 million."

Mr. McDermott continued, "We accelerated the full domestic launch of the IntuiTrak(TM) Express Delivery System into the second quarter based on very positive feedback during its limited release in early 2009. We believe this next generation product enhances our ability to strengthen customer relationships by offering a single low-profile delivery platform that can be utilized to treat a wide variety of patient anatomies, including those with aortic necks up to 32 mm in diameter. Physicians continue to provide positive feedback on IntuiTrak's clinical benefits, flexibility and ease-of-use and we look forward to further broadening our customer base."

Financial Results

Total revenue in the second quarter of 2009 was $13.2 million, a 42% increase from $9.3 million in the second quarter of 2008, and an 11% increase from $11.8 million in the first quarter of 2009. Domestic revenue was $11.4 million, a 45% increase compared with $7.9 million in the second quarter of 2008, and a 12% increase compared with $10.2 million in the first quarter of 2009. International revenue was $1.8 million, a 27% increase compared with $1.4 million in the second quarter of 2008 and a 6% increase compared with $1.7 million in the first quarter of 2009. For the six months ended June 30, 2009, total revenue increased 42% to $25.0 million, compared with $17.6 million for the six months ended June 30, 2008.

Gross profit was $9.9 million in the second quarter of 2009, representing a gross margin of 75%. This compares with gross profit of $6.7 million and a gross margin of 72% in the second quarter of 2008. Gross profit was $18.8 million for the six months ended June 30, 2009, representing a gross margin of 75%. This compares with gross profit of $12.5 million and a gross margin of 71% for the six months ended June 30, 2008. Higher gross margins for the three and six months ended June 30, 2009 were driven by faster growth in domestic revenue, more favorable product mix and lower cost of sales due to volume efficiencies.

Total operating expenses were $10.3 million in the second quarter of 2009, compared with $10.5 million in the second quarter of 2008. Marketing and sales expenses increased to $6.6 million in the second quarter of 2009 from $6.1 million in the same period last year. Research, development and clinical expenses decreased to $1.5 million in the second quarter of 2009 from $1.8 million in the same period last year. General and administrative expenses decreased to $2.3 million in the second quarter of 2009 from $2.6 million in the same period last year.

Total operating expenses for the six months ended June 30, 2009 were $20.3 million, compared with $20.1 million for the six months ended June 30, 2008. Marketing and sales expenses increased to $13.2 million in the first six months of 2009, up from $11.9 million in the same period last year. Research, development and clinical expenses decreased to $2.8 million in the first six months of 2009, down from $3.3 million in the same period last year. General and administrative expenses decreased to $4.3 million in the first six months of 2009, down from $4.9 million in the same period last year.

Endologix reported a net loss for the second quarter of 2009 of $425,000, or $0.01 per share, compared with a net loss of $3.8 million, or $0.09 per share, for the second quarter of 2008. For the six months ended June 30, 2009, the Company reported a net loss of $1.6 million, or $0.04 per share, compared with a net loss of $7.5 million, or $0.17 per share, for the six months ended June 30, 2008.

Total cash and cash equivalents increased by $1.0 million during the second quarter and by $236,000 for the first six months of 2009. Total cash and cash equivalents were $7.8 million as of June 30, 2009, compared with total cash and cash equivalents of $7.6 million as of December 31, 2008.

"In the second quarter we achieved our goal of positive cash flow from operations. We expect to continue to be cash flow positive through 2009 and beyond as we achieve greater sales force efficiencies and further leverage our corporate infrastructure," stated Endologix Chief Financial Officer Bob Krist.

Conference Call Information

Endologix management will host a conference call to discuss these topics today beginning at 5:30 p.m. Eastern time (2:30 p.m. Pacific time). To participate via telephone please call (877) 407-0789 from the U.S. or (201) 689-8562 from outside the U.S. A telephone replay will be available for seven days following the completion of the call by dialing (877) 660-6853 from the U.S. or (201) 612-7415 from outside the U.S., and entering account number 3055 and conference ID number 327805. The conference call will be broadcast live over the Internet at www.endologix.com and will be available for 30 days.

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

Except for historical information contained herein, this news release contains forward-looking statements, specifically with respect to increasing the number of customers for the Powerlink System, achieving certain annual revenues, and remaining cash flow positive in future quarters, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including the success of sales efforts for the Powerlink System and related new products, product research and development efforts, and other economic, business, competitive and regulatory factors. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.

    COMPANY CONTACT:                  INVESTOR CONTACTS:
    Endologix, Inc.                   The Ruth Group
    John McDermott, CEO               Nick Laudico (646) 536-7030
    (949) 595-7200                    Zack Kubow (646) 536-7020
    www.endologix.com




                                   ENDOLOGIX, INC.
                  CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

                      (In thousands, except per share amounts)
                                    (Unaudited)

                                     Three Months Ended    Six Months Ended
                                         June 30,             June 30,
                                      2009      2008       2009      2008
                                      ----      ----       ----      ----
    Revenue:
      Domestic Product Revenue      $11,410    $7,881   $21,586   $14,730
       Non - U.S. Product Revenue     1,758     1,380     3,416     2,848
                                     ------     -----    ------    ------
    Total Product Revenue:           13,168     9,261    25,002    17,578
      License revenue                   ---        12       ---        24
                                     ------     -----    ------    ------
    Total revenue                    13,168     9,273    25,002    17,602
      Cost of product revenue         3,256     2,554     6,161     5,085
                                     ------     -----    ------    ------
    Gross profit                      9,912     6,719    18,841    12,517
                                     ------     -----    ------    ------
    Gross profit as a % of total
     revenue                            75%       72%       75%       71%
    Operating expenses:
      Research, development and
       clinical                       1,469     1,798     2,824     3,296
      Marketing and sales             6,570     6,144    13,192    11,944
      General and administrative      2,260     2,599     4,328     4,871
                                     ------    ------    ------    ------
    Total operating expenses         10,299    10,541    20,344    20,111
                                     ------    ------    ------    ------
    Loss from operations               (387)   (3,822)   (1,503)   (7,594)
                                     ------    ------    ------    ------
    Other income:
         Other                          (38)       60       (99)      140
                                     ------    ------    ------    ------
    Net loss                          $(425)  $(3,762)  $(1,602)  $(7,454)
                                     ======    ======    ======    ======
    Basic and diluted net loss
     per share                       $(0.01)   $(0.09)   $(0.04)   $(0.17)
                                     ======    ======    ======    ======
    Shares used in computing basic
     and diluted net loss per share  43,351    42,976    43,348    42,964
                                     ======    ======    ======    ======



                                   ENDOLOGIX, INC.
                        CONDENSED CONSOLIDATED BALANCE SHEETS
                                     Unaudited
                                   (In thousands)

                                                  June 30,     December 31,
                                                    2009          2008
                                                  --------     ------------
    ASSETS
    Current assets:
       Cash and cash equivalents                   $7,847          $7,611
       Restricted cash equivalents                    500             500
       Accounts receivable, net                     8,154           6,371
       Other receivables                               15               3
       Inventories                                  7,241           7,099
       Other current assets                           283             443
                                                  -------         -------
          Total current assets                     24,040          22,027
    Property and equipment, net                     2,630           2,993
    Goodwill                                        4,631           4,631
    Intangibles, net                                6,806           7,508
    Other assets                                       96             104
                                                  -------         -------
         Total Assets                             $38,203         $37,263
                                                  =======         =======
    LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities:
    Accounts payable and accrued expenses          $6,023          $5,401
    Current portion of long term debt               1,077             750
                                                  -------         -------
         Current liabilities                        7,100           6,151
    Long term liabilities:
    Long term debt                                  3,873           4,250
    Other long term liabilities                     1,029           1,045
                                                  -------         -------
         Long term liabilities                      4,902           5,295
                                                  -------         -------
           Total liabilities                       12,002          11,446
                                                  -------         -------
    Stockholders' equity:
       Common stock, $.001 par value; 75,000
        shares authorized, and 44,875 and 44,365
         shares issued, and 44,380 and 43,870
          outstanding                                  45              44
    Additional paid-in capital                     72,176         170,239
    Accumulated deficit                          (145,332)       (143,730)

    Treasury stock at cost, 495 shares               (661)           (661)
    Accumulated other comprehensive income            (27)            (75)
                                                  -------         -------
         Total stockholders' equity                26,201          25,817
                                                  -------         -------
         Total Liabilities and Stockholders'
          Equity                                  $38,203         $37,263
                                                  =======         =======


'/>"/>
SOURCE Endologix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Endologix to Report Second Quarter 2009 Financial Results on July 22, 2009
2. Endologix Added to Russell Indexes
3. Endologix Announces Live Web Cast of Presentation in SMH Capital Small Cap Spotlight on June 17, 2009 at 4:15 p.m. ET
4. Endologix Receives Nasdaq Letter on Director Independence
5. Endologix Announces Full Commercial Launch of IntuiTrak Express Delivery System
6. Universal Health Realty Income Trust Reports 2009 Second Quarter Financial Results
7. Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance
8. Amylin Pharmaceuticals Reports Second Quarter Financial Results
9. Quest Diagnostics Reports Strong Performance in Second Quarter 2009
10. Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Earnings Growth Outlook for 2009
11. Income at Risk: Unemployment Reaches Nine-Month High for Those with Disabilities, Reports Allsup
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
Breaking Medicine Technology: